Details for New Drug Application (NDA): 021842
✉ Email this page to a colleague
NDA 021842 describes ACTOPLUS MET, which is a drug marketed by Takeda Pharms Usa and is included in two NDAs. It is available from one supplier. There are four patents protecting this drug and two Paragraph IV challenges. Additional details are available on the ACTOPLUS MET profile page.
The generic ingredient in ACTOPLUS MET is metformin hydrochloride; pioglitazone hydrochloride. There are forty-nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; pioglitazone hydrochloride profile page.
The generic ingredient in ACTOPLUS MET is metformin hydrochloride; pioglitazone hydrochloride. There are forty-nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; pioglitazone hydrochloride profile page.
Summary for 021842
| Tradename: | ACTOPLUS MET |
| Applicant: | Takeda Pharms Usa |
| Ingredient: | metformin hydrochloride; pioglitazone hydrochloride |
| Patents: | 2 |
Suppliers and Packaging for NDA: 021842
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ACTOPLUS MET | metformin hydrochloride; pioglitazone hydrochloride | TABLET;ORAL | 021842 | NDA | Takeda Pharmaceuticals America, Inc. | 64764-158 | 64764-158-18 | 180 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (64764-158-18) |
| ACTOPLUS MET | metformin hydrochloride; pioglitazone hydrochloride | TABLET;ORAL | 021842 | NDA | Takeda Pharmaceuticals America, Inc. | 64764-158 | 64764-158-41 | 4 CARTON in 1 TRAY (64764-158-41) / 1 BLISTER PACK in 1 CARTON / 7 TABLET, FILM COATED in 1 BLISTER PACK |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 500MG;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Aug 29, 2005 | TE: | RLD: | Yes | |||||
| Patent: | 9,101,660 | Patent Expiration: | Jan 22, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | 9,320,714 | Patent Expiration: | Feb 3, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 850MG;EQ 15MG BASE | ||||
| Approval Date: | Aug 29, 2005 | TE: | AB | RLD: | Yes | ||||
| Patent: | 9,101,660 | Patent Expiration: | Jan 22, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Expired US Patents for NDA 021842
Complete Access Available with Subscription
